HYPERA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.15 BRL | -3.38% |
|
-8.59% | -24.06% |
| Apr. 29 | Transcript : Hypera S.A., Q1 2024 Earnings Call, Apr 29, 2024 | |
| Apr. 27 | Hypera S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 8.62B 1.64B | Sales 2025 * | 9.39B 1.79B | Capitalization | 17.19B 3.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.81B 346M | Net income 2025 * | 2.1B 401M | EV / Sales 2024 * | 2.84 x |
| Net Debt 2024 * | 7.29B 1.39B | Net Debt 2025 * | 6.85B 1.31B | EV / Sales 2025 * | 2.56 x |
| P/E ratio 2024 * |
9.54
x | P/E ratio 2025 * |
8.3
x | Employees | 10,301 |
| Yield 2024 * |
4.56% | Yield 2025 * |
5.17% | Free-Float | 58.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hypera S.A.
| 1 day | -3.38% | ||
| 1 week | -8.59% | ||
| 1 month | -8.03% | ||
| 3 months | -20.61% | ||
| 6 months | -20.61% | ||
| Current year | -24.06% |
1 week
26.72
30.35
1 month
26.7231.06
Current year
26.7236.34
1 year
26.7246.84
3 years
26.2551.11
5 years
26.0751.11
10 years
14.0651.11
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 36 | 22-02-23 | |
| Compliance Officer | 40 | 07-12-31 | |
| Investor Relations Contact | 43 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | - | |
| Director/Board Member | 58 | - | |
| Director/Board Member | 50 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.79% | 2 M€ | -14.14% | ||
| 0.92% | 17 M€ | -8.09% | - | |
| 0.86% | 14 M€ | -4.02% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 27.15 | -3.38% | 6,569,900 |
| 24-05-29 | 28.1 | -6.02% | 8,169,500 |
| 24-05-28 | 29.9 | -0.17% | 6,718,400 |
| 24-05-27 | 29.95 | +0.84% | 1,168,500 |
| 24-05-24 | 29.7 | -1.30% | 3,132,200 |
Delayed Quote Sao Paulo, May 31, 2024 at 04:07 pm EDT
More quotes
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
27.15
BRL
Average target price
39.8
BRL
Spread / Average Target
+46.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.06% | 3.28B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- HYPE3 Stock
